STOCK TITAN

POSITRON CORP - POSC STOCK NEWS

Welcome to our dedicated page for POSITRON news (Ticker: POSC), a resource for investors and traders seeking the latest updates and insights on POSITRON stock.

Positron Corporation is a nuclear medicine healthcare company specializing in the field of cardiac Positron Emission Tomography (PET) imaging. With over 30 years of focus on cardiac PET, Positron aims to make this superior modality more accessible to clinicians and patients worldwide. Their Attrius® system, optimized for MPI, offers cutting-edge technology and accurate diagnostic capabilities in cardiac imaging.

Rhea-AI Summary
Positron welcomes a prominent cardiovascular practice in California as a new customer utilizing Positron's Attrius PET System and services. The company anticipates entering five more Attrius Lease to Own/Services agreements by year's end. Positron's PET Lease to Own & Services Program offers a complete package with zero upfront capex expense, providing a viable operational model for nuclear imaging PET practices. The company aims to provide hospitals and private practices with the best technology, services, and solutions to meet customer needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Positron Corporation to begin clinical study of Affinity PET-CT imaging device with Ochsner Clinic Foundation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
-
Rhea-AI Summary
Positron Corporation (POSC) Announces Business Cooperative Partnership and Acquisition of PET Imaging Systems Inventory
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.73%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.64%
Tags
none
-
Rhea-AI Summary

Positron Corporation (OTC: POSC) has entered a Clinical Study/Research Agreement with Ochsner Clinic Foundation for its new Affinity™ PET-CT 4D device. This agreement facilitates the collection of safety and efficacy data, crucial for obtaining an Investigational Device Exemption (IDE) from the FDA. The independent Institutional Review Board has approved all study procedures, allowing preparations for patient scans to begin post-IDE approval. The company aims for completion of the clinical study and FDA certification within 60 days, marking a significant step toward commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
Rhea-AI Summary

Positron Corporation (OTC: POSC) announces a collaboration with Dr. Robert Bober and Ochsner Health for a clinical study of its new Affinity PET-CT 4D imaging device. This FDA-compliant study, commencing mid-January 2023, aims to evaluate the device's image quality and performance in cardiac PET imaging. Dr. Bober's leadership is pivotal for gathering empirical data essential for marketing the system. Following completion and FDA 510k certification, Positron intends to commercialize the device in Q1 2023, targeting nuclear cardiology and oncology markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Positron Corporation (OTC: POSC) has announced the purchase of its first Affinity PET-CT system from Neusoft Medical Systems, which is currently in transit to the U.S. for validation. This marks a crucial step in launching the device, aimed at cardiac and oncology imaging. The company plans to reveal details about participating hospitals and expects to submit a 510K application to the FDA soon. President Adel Abdullah highlighted the excitement among industry partners for the upcoming validation studies, set to begin in September and conclude by November 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Positron Corporation (OTC: POSC) announced the appointment of Christopher Reilly to lead its PET-CT Services and Systems Sales. With over 30 years of experience in SPECT imaging, Reilly aims to facilitate the transition from SPECT to PET imaging for hospitals and cardiology practices. The company will validate its new PET-CT device in collaboration with a leading healthcare organization over the next three months. President Adel Abdullah expressed confidence in Reilly's expertise, which is expected to support Positron's sales and marketing initiatives as it prepares to launch its new product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
Rhea-AI Summary

Positron Corporation (OTC: POSC) announced its partnership with Medical Device Academy (MDA) to assist in the 510K submission for its new PET/CT device to the FDA. The company aims to file the application within 60 days, seeking approval within 100 days of filing. President Adel Abdullah highlighted MDA's expertise as crucial for the application process. This advancement is part of Positron's strategy to enhance cardiac and oncology diagnostics, positioning its innovative PET technology to meet market demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Positron Corporation (OTC: POSC) has announced a collaboration with Neusoft Medical Systems to develop a new PET/CT imaging system, marking a significant expansion into the oncology market. The company plans to submit a 510K application to the FDA soon. With an expected market size of $3.34 billion by 2028, Positron aims for a 10% market share. The new system promises superior imaging capabilities, thus enhancing diagnostic accuracy in nuclear cardiology and oncology. Positron emphasizes growth through transparency and is focused on expanding its marketing and sales efforts in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none

FAQ

What is the current stock price of POSITRON (POSC)?

The current stock price of POSITRON (POSC) is $1.087 as of December 23, 2024.

What is the market cap of POSITRON (POSC)?

The market cap of POSITRON (POSC) is approximately 27.2M.

What is Positron Corporation known for?

Positron Corporation specializes in cardiac Positron Emission Tomography (PET) imaging, focusing on providing advanced technology for accurate diagnosis of heart disease.

What is the significance of cardiac PET imaging?

Cardiac PET imaging is recognized as the gold standard in diagnostic nuclear imaging, particularly for detecting coronary artery disease with superior accuracy.

What is the Attrius® system by Positron Corporation?

The Attrius® system is the latest advancement in cardiac PET technology, offering excellent sensitivity and minimal radiation exposure for improved diagnostic capabilities in heart disease.

How does Positron Corporation aim to make cardiac PET more accessible?

Positron Corporation is committed to minimizing barriers of entry and increasing the accessibility of cardiac PET imaging technology to clinicians and patients globally.

How long has Positron Corporation been supporting cardiac PET?

Positron Corporation has been exclusively focused on supporting cardiac PET for over 30 years, demonstrating their dedication to advancing nuclear medicine in the field of cardiology.

What are the benefits of using the Attrius® system for cardiac imaging?

The Attrius® system enables healthcare providers to more accurately diagnose heart disease, improve patient outcomes, and practice cost-effective medicine through routine quantitative measurements and advanced technology.

Where can I find more information about Positron Corporation?

For further information, visit the company's website at www.positron.com or contact the Investor Relations team at investor@positron.com.

Who do I contact for Investor Relations at Positron Corporation?

Investors can reach out to Lisa Gray, Senior Account Manager at Skyline Corporate Communications Group, LLC, located at One Rockefeller Plaza, 11th Floor, New York, NY 10020. Contact Lisa at (646) 893-5835 or email at lisa@skylineccg.com for more information.

What type of imaging technology does Positron Corporation specialize in?

Positron Corporation specializes in cardiac Positron Emission Tomography (PET) imaging, offering advanced technology and superior diagnostic accuracy in nuclear cardiology.

How does the Attrius® system compare to other imaging modalities?

The Attrius® system excels in providing excellent sensitivity and minimal radiation exposure compared to SPECT imaging, making it a preferred choice for accurate and safe cardiac imaging.

What makes Positron Corporation a leader in cardiac PET imaging?

Positron Corporation's exclusive focus on cardiac PET for over 30 years, along with their commitment to advancing technology and increasing accessibility, positions them as a leader in nuclear medicine for heart disease diagnosis.

POSITRON CORP

OTC:POSC

POSC Rankings

POSC Stock Data

27.23M
23.43M
Medical Devices
Healthcare
Link
United States of America
Niagara Falls